Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06356688
Other study ID # 13914704178
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date April 20, 2024
Est. completion date June 20, 2025

Study information

Verified date April 2024
Source The First Affiliated Hospital with Nanjing Medical University
Contact Jing Sun
Phone 13914704178
Email sunj@njmu.edu.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (cadonilimab) in combination with platinum-containing chemotherapy (paclitaxel polymer micelles combined with cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with cadonilimab combined with chemotherapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date June 20, 2025
Est. primary completion date April 20, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age =18 years, =75 years, gender is not limited; 2. Squamous esophageal cancer of thoracic segment confirmed by pathology; 3. Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable after discussion among oncology, esophageal surgery, and imaging, and clinical stage cT2-4aN+ or cT3-4aN0, M0, stage II, III, or IVA (AJCC 8th edition cTNM staging); 4. ECOG PS score of 0-1; 5. No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy; 6. Expected survival > 6 months; 7. Adequate baseline organ function: (i) WBC =3×10^9/L, ANC =1.5×10^9/L, PLT =100×10^9/L, Hb =9g/dL; (ii) Liver function: TBIL =2ULN, AST =2.5ULN, ALT =2.5ULN; (iii) Renal function: cCr>40 ml/min, Cr=1.5 ULN; (iv) Cardiac function: no cardiac disease or coronary artery disease. Cardiac function: no heart disease or coronary heart disease, patients with cardiac function grade 1-2; 8. Hypertensive patients applying antihypertensive drugs to control blood pressure within the normal range; 9. Diabetic patients with fasting blood glucose controlled at =8mmol/L by hypoglycemic drug treatment; 10. No other serious diseases (such as autoimmune diseases, immunodeficiency, organ transplantation, or other diseases that require continuous hormone therapy) that conflict with this protocol; 11. No history of other malignant tumors; 12. The patient agrees to participate in this clinical study and signs the Informed Consent Form. Exclusion Criteria: 1. Patients who have previously received anti-tumor therapy (including chemotherapy, radiotherapy, surgery or immunotherapy, etc.); 2. Combination of other incurable malignant tumors (except cured non-malignant skin tumors, cervical cancer in situ, and prostate cancer); 3. Patient has or anticipates a significant risk of esophageal perforation, fistula, and hemorrhage; 4. Active autoimmune or immunodeficiency disease, use of immunosuppressants prior to enrollment, and use of immunosuppressant dosage =10 mg/day of oral prednisone for more than 2 weeks; 5. Clinically significant cardiovascular disease including, but not limited to, severe acute myocardial infarction, unstable or severe angina pectoris, coronary artery bypass grafting surgery, congestive heart failure, ventricular arrhythmia requiring medical intervention, left ventricular ejection fraction <50%, or other anticipated inability to tolerate chemoradiotherapy in the 6 months prior to enrollment; 6. Severe allergies; 7. Pregnant or lactating women; 8. Severe mental disorders; 9. Presence of CTC grade =3 peripheral nerve disease; 10. Abnormal coagulation function (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), bleeding tendency or undergoing thrombolytic or anticoagulant therapy; 11. Presence of severe pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, severe impairment of lung function, or active tuberculosis within 1 year; 12. Presence of active hepatitis B or C; 13. Any other condition that the investigator evaluates to be ineligible for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
paclitaxel polymer micelles and cisplatin combined with Cadonilimab
Paclitaxel polymer micelles:Cycle 1: 230mg/m2, IV =3 hours; Cycles 2-4: If the patient has a neutrophil nadir =1.0 x 109/L along with a platelet nadir =80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV =3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 375mg, IV drip, d3, q3w;

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sun Jing

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological complete response (pCR) rates evaluate pathological complete response rate of primary tumor and locally metastatic lymph nodes after 2-4 cycles of neoadjuvant therapy. From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks.
Secondary Objective Rate of Effectiveness (ORR) the proportion of patients who achieve PR or CR From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks.
Secondary R0 Removal Rate Rate of microscopically margin-negative resection From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks.
Secondary 2-year overall survival rate 2-year overall survival rate 2 years
Secondary 2-year disease free survival rate 2-year disease free survival rate 2 years
Secondary major pathological response (MPR) From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 12 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05996484 - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma Phase 2
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Recruiting NCT06138496 - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Phase 2
Not yet recruiting NCT05983094 - Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer Phase 2
Terminated NCT04440982 - Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Phase 2
Recruiting NCT04028375 - Study of CT and MR in the Gastric Cancer
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT04588987 - Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT05993858 - Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC Phase 2
Active, not recruiting NCT04666090 - Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04848454 - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Phase 2
Recruiting NCT04062058 - A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06124378 - Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Phase 2
Not yet recruiting NCT06125223 - PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Not yet recruiting NCT06404736 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer Phase 2
Not yet recruiting NCT06404463 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer Phase 2
Recruiting NCT05371197 - Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer Phase 2
Recruiting NCT06212440 - Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy N/A
Completed NCT03178032 - Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Phase 1